Scarica l'app Stockscreener
105.39
2.09%
2.16
Pre-mercato:
106.89
1.50
+1.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte bolsters haematology portfolio in $2bn Vega buyout - MSN
Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore! - Smartkarma
Daily Brief Health Care: Laurus Labs, Ascendis Pharma, GSK , Incyte Corp, Insmed Inc, Johnson & Johnson, Kardigan, LogicMark, Parabilis Medicines, Solventum and more - Smartkarma
Incyte to Acquire Vega Therapeutics from Star Therapeutics for Up to $2 Billion - Global Legal Chronicle
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Why Incyte (INCY) Stock Is Up Today - Yahoo Finance
Incyte (INCY) director Jacqualyn Fouse awarded RSUs and 6,111 stock options - Stock Titan
H.C. Wainwright raises Incyte stock price target to $140 on Vega deal - Investing.com
Incyte to buy Vega Therapeutics in hematology deal worth up to $2B - MSN
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B - Yahoo! Finance Canada
INCY Maintains Rating by HC Wainwright & Co. -- Price Target Rai - GuruFocus
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster PotentialIncyte (NASDAQ:INCY - Benzinga
Incyte to acquire blood disorder drug candidate for $2B - Delaware Business Times
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition - Investing.com
Stifel reiterates Incyte stock Buy rating on VGA039 acquisition By Investing.com - Investing.com UK
Incyte Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT - MSN
Incyte Corporation (INCY) Announces Acquisition of Vega Therapeu - GuruFocus
Incyte makes $2 billion bet on bleeding disorder drug ahead of Jakafi patent cliff - MSN
Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B - Law360
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Three Bay Area biotech startups ink big-company deals potentially totaling $5 billion - The Business Journals
Oppenheimer raises Incyte stock price target on Vega acquisition By Investing.com - Investing.com Nigeria
Oppenheimer raises Incyte stock price target on Vega acquisition - Investing.com India
Incyte To Acquire Vega Therapeutics For Up To $2 Billion To Expand Hematology Portfolio Into Bleeding Disorders - Pulse 2.0
Incyte (INCY) to Acquire Vega Therapeutics for $1.25B - GuruFocus
Incyte to acquire Vega Therapeutics in deal valued at up to $2B - The Business Journals
Incyte to acquire Star subsidiary Vega Therapeutics - The Pharma Letter
Incyte acquires Vega Therapeutics in $1.25 billion deal - grafa.com
Incyte Acquires Vega Therapeutics for $2 Billion, Expanding Hematology Portfolio with Phase 3 Bleeding Disorder Drug VGA039 - Minichart
Incyte to Acquire Vega Therapeutics in Up to $2 Billion Hematology Expansion - citybiz
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders - BioSpace
Incyte Study Shows Lymphoma Regimen Extends Progression-Free Survival - MyChesCo
Incyte makes Vega deal official, paying $1.25B upfront for bleeding disorder biotech - FirstWord Pharma
Incyte to buy company in late stages of development of bleeding control drug - Delaware Business Now
Incyte to buy blood disorder drug in possibly $2B deal - Yahoo Finance
Incyte to acquire Vega Therapeutics for $1.25B, up to $2.0B with milestones; VGA039 Phase 3 asset - TradingView
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary - Yahoo Finance
BRIEF—Incyte eyeing acquisition of Star Therapeutics - The Pharma Letter
Incyte Corp. (INCY) Nears $2 Billion Acquisition of Star Therape - GuruFocus
Incyte Corp. (INCY) Nears $2 Billion Acquisition of Star Therapeutics - GuruFocus
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT (INCY:NASDAQ) - Seeking Alpha
Incyte to buy bleeding disorder drug candidate in deal valued at up to $2 billion - Delaware Business Now
Incyte to Present Strategy Update at Goldman Sachs Healthcare Conference - MyChesCo
ETFs Investing in Incyte Corporation Stocks - TradingView
From Spotlight Delaware: Incyte’s sale of Wilmington offices generates 10 cents in real estate taxes - Delaware Business Now
Is Tafasitamab’s First-Line DLBCL Win Reframing The Investment Case For Incyte (INCY)? - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability - ChartMill
Incyte’s sale of Wilmington offices generates just 10 cents in real estate taxes - Spotlight Delaware
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - Barchart
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
INCY insider files Form 144 to sell 2,639 shares (INCY) - Stock Titan
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo Finance
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com
Mirum and Incyte to present zilurgisertib study results at ENDO 2026 - StreetInsider
2.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):